trial · primary record
MTBVAC
Tuberculosis (TB)
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 5531 |
| Primary completion | 2028-12-31 |
| Primary endpoint | To evaluate the protective efficacy of MTBVAC against bacteriologically confirmed PTB, not associated with HIV infection, diagnosed by more than one diagnostic test with sputum obtained before initiation of TB treatment, in baseline IGRA-positives. |
| Registry ID | NCT06272812 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:03.573Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06272812
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.